Abstract
Purpose :
To investigate predictive factors for subthreshold micropulse laser (SML) treatment in chronic central serous chorioretinopathy (cCSC).
Methods :
In this prospective study, patients with cCSC were included and treated with navigated 577 nm SML. A complete ophthalmological evaluation including spectral optical coherence tomography (SD-OCT), fluorescein angiography (FA) and microperimetry (MP) was performed. FA hyperfluorescence patters were also analyzed.
Results :
Overall, 38 eyes from 38 patients (48.20 ± 5.95 years of age) affected by cCSC were included. The cohort was stratified into 2 groups: group 1 (31 eyes, 81,6%), which demonstrated successful response to treatment at 3 months and group 2 (7 eyes, 18.4%), which did not. In Group 1, a significant improvement of best correct visual acuity was observed at all timepoints from baseline (p < 0.05), whereas in Group 2 significantly varied only at month 1 (p<0.05),
Only Group 1 exhibited a significant improvement in mean macular sensitivity at 6 months (+2.08 dB, p: 0.03) and 12 months (+2.56 dB, p <0.001).
Logistic regression analysis revealed that eyes with subretinal hyperreflective material (SHRM, p: 0.044; OR: -0.225; 95% CI: -0.448 - -0.003) and focal hyperfluorescence pattern on FA (p<0.001; OR: 0.438; 95% CI: 0.196-0.632) predicted treatment response.
Conclusions :
The results of our study showed that SML can be considered a safe and effective treatment option for patients with cCSC, highlighting the potential importance of FA hyperfluorescence pattern and presence of SHRM in predicting the functional outcomes.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.